Thomas A. Russo MD
Thomas A. Russo
MD
SUNY Distinguished Professor; Professor and Chief, Infectious Disease
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Infectious Disease; Microbial Pathogenesis
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDProfessional Summary:
I am an expert in infectious diseases, and I care for hospitalized patients at the Buffalo VA Medical Center (Buffalo VAMC).
I have an active, nationally funded translational research program. My research focuses on Gram-negative bacilli (GNB), including Escherichia coli, Acinetobacter baumannii and a new hypervirulent variant of Klebsiella pneumoniae.
These GNB cause infection in nearly every non-intestinal site in the body. The hypervirulent variant of K. pneumoniae is both fascinating and worrisome. Unlike its predecessors, it is capable of causing infection in young, healthy hosts and spreading nearly anywhere in the body from the initial infected site, including the eyes and brain. GNB-caused infections result in the loss of billions of health care dollars, millions of work days and hundreds of thousands of lives each year.
GNB are becoming increasingly resistant to antibiotics, including strains that have become resistant to all available antibiotics. Unfortunately, there are virtually no new antimicrobial agents active against highly resistant GNB in the pharmaceutical “pipeline.” To address this formidable clinical challenge, my collaborators and I have increased our understanding of the bacterial factors that are critical for these GNB to cause infection. We use this information to develop vaccines that will prevent infection and antibodies that can be used to treat infection. My UB collaborators include Dr. Campagnari (microbiology) and Dr. Gulick (structural biology). My research also involves identifying potential bacterial drug targets; this information will be used to develop new classes of antibiotics.
I intermittently have students in my lab, and I participate in a grant designed to encourage medical students to become physician-scientists. I welcome interested students to contact me about conducting research with me.
The Buffalo VAMC is the site of my clinical teaching. I teach first- and second-year medical students in lecture settings and small group sessions, including courses in lung respiration, musculoskeletal, renal and microbiology-immunology. Residents attend my grand rounds; I also teach fellows in all aspects of their training and mentor those who perform their research projects in my lab.
Since the advent of the COVID-19 pandemic I have served as a resource to educate and inform healthcare providers, the public, and businesses on how to best manage this evolving crisis as well as other topical infectious diseases issues.
Education and Training:
- Certificate, Management, University at Buffalo School of Management (2015)
- Fellowship, Infectious Disease, Tufts-New England Medical Center (1988)
- Medicine, Harvard-New England Deaconess Hospital (1985)
- McGill University (1982)
Employment:
- Chief, Division of Infectious Diseases, Medicine, Veterans Administration Western New York Healthcare System (2024-present)
- Chief, Division of Infectious Diseases, Medicine, UB School of Medicine (2009-present)
- Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1994-present)
- Vice Chair of Finance, Department of Medicine, University at Buffalo (2012–2019)
- Honorary Board member, Shanghai Public Health Board (2012)
- Senior Staff Fellow, Laboratory of Clinical Investigation, National Institutes of Health National Institute of Allergy and Infectious Diseases (1989–1994)
- Clinical Assistant Instructor, Division of Geographic Medicine and Infectious Diseases, Tufts University (1988–1989)
Awards and Honors:
- Excellence in Health care award (2024)
- Fellow-American Association for the Advancement of Science (AAAS) (2024)
- Top Doctors (2024)
- George F. Koepf Award (2023)
- Inducted into Alpha Omega Alpha (2023)
- Top Doctors (2023)
- Top Doctors (2022)
- The Chancellor Charles P. Norton Medal (2021)
- SUNY Distinguished Professor (2021)
- Dean's Award-Jacobs School of Medicine and Biomedical Sciences (2020)
- Veterans Administration Biomedical Laboratory R&D Senior Clinical Scientist Award (2019)
- Stockton Kimball Award (2017)
- University at Buffalo Exceptional Scholar Sustained Achievement Award (2012)
- Visionary Inventor: UB technology licensed to Zeptometrix Corp. (2009)
- Top 100 Principal Investigators at the University at Buffalo (2005)
- SUNY Inventor award (for U.S. patent # patent 6,410,703) (2003)
- Top 100 Federal Grantees at the University at Buffalo (2002)
- F. Carter Pannill Award (1997)
- IDSA-Stuart Pharmaceutical Fellowship in Infectious Diseases (1987)
- Hinton Book Award-Residency-Harvard-NE Deaconess Hospital (1985)
- James McGill Award-McGill University (1981)
- James McGill Award-McGill University (1980)
- Faculty Scholar-McGill University (1980)
- University Scholar-McGill University (1979)
Research Expertise:
- Acinetobacter baumannii pathogenesis
- Actinomycosis: infections caused by the genera Actinomyces
- Bisphosphonate-induced osteonecrosis
- Drug development: A. baumannii
- Enteric gram-negative bacilli: Infections caused by Gram-negative bacilli
- Extraintestinal pathogenic Escherichia coli pathogenesis: pathogenesis vaccine development
- Host-pathogen interactions: Understanding mechanisms by which extraintestinal patghogenic E. coli modify host defenses
- Identification of antimicrobial targets
- Klebsiella pneumoniae pathogenesis: drug target identification pathogenesis biofilms
- Microbial pathogenesis: Understanding the mechanisms by which extraintestinal pathogenic E. coli, Acinetobacter, and Klebsiella cause disease
- Pathogenesis of urinary tract infection
- Vaccine development: Extraintestinal pathogenic E. coli, Klebsiella pneumoniae, and Acinetobacter
Research Centers:
- Witebsky Center for Microbial Pathogenesis and Immunology
Grants and Sponsored Research:
- October 2019–September 2027
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannii
Veterans Administration
Role: Principal Investigator
$1,359,244 - September 2022–August 2027
Mab Passive Vaccination against Acinetobacter baumannii
NIAID/NIH
Role: Co-Investigator
$485,053 - May 2022–April 2027
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
NIAID/NIH
Role: Co-Investigator - August 2020–July 2024
Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae.
NIH
Role: Principal Investigator
$431,682 - September 2017–August 2022
Mab Passive Vaccination against Acinetobacter baumannii
NIH
Role: Co-Investigator
$491,635 - August 2018–August 2021
DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii
NIH/NIAID
Role: Co-Principal Investigator
$981,697 - February 2016–January 2020
Development of a HTP Assay for Inhibitors of Aerobactin Production
NIH
Role: Co-Investigator
$358,875 - March 2016–February 2019
Development of a diagnostic test for hypervirulent Klebsiella pneumoniae
NIH
Role: Principal Investigator
$438,625 - February 2016–January 2019
Development of HTP Assay for Inhibitors of Aerobactin Production(R01AI116998)
National Institutes of Health
Role: Co-Investigator - March 2015–February 2016
Purification and identification of ascitocin, a novel or unrecognized antibiotic of human origin
UB-SUNY
Role: Co-Principal Investigator
$35,000 - August 2014–February 2016
Monoclonal antibody passive vaccination to treat XDR Acinetobacter infections
NIH
Role: Co-Investigator
$39,750 - April 2011–March 2015
Analysis of A. baumannii capsule as a vaccine candidate
Veterans Administration
Role: Principal Investigator
$604,476 - September 2011–October 2014
Identification of New Drug Targets in Multi-Drug Resistant Bacterial Infections
Department of Defense (DOD)
Role: Co-Principal Investigator
$1,744,854 - October 2010–October 2013
Electrical Stimulation of Titanium for the Prevention and/or Eradication of A. baumannii and S. aureus Biofilm Infections on Osseointegrated Prostheses
Congressionally Directed Medical Research Program-Peer Reviewed Orthopaedic Research Program
Role: Co-Investigator
$621,591 - August 2011–July 2013
Identification of genes essential for survival of hypervirulent Kleb. pneumonia
NIH
Role: Principal Investigator
$435,875 - March 2007–April 2012
Pathogenesis of Aspiration Pneumonitis
NIH
Role: Co-Investigator
$1,981,250 - July 2001–June 2005
The Pathogenesis of Grand Negative Bacillary Pneumonia
US Dept of Health, Education and Welfare
Role: Principal Investigator
Patents:
- Identification of a vaccine candidate from an extraintestinal isolate of E A potential vaccine candidate or diagnostic tool for infections due to extraintestinal pathogenic E. coli
Journal Articles:
- Russo TA, Carlino-MacDonald U, Drayer ZJ, Davies CJ, Alvarado CL, Hutson A, Luo TL, Martin MJ, McGann PT, Lebreton F. (2024) Deciphering the relative importance of genetic elements in hypervirulent Klebsiella pneumoniae to guide countermeasure development. EBioMedicine (Aug), 107: 105302.
- Kumar A, Chakravorty S, Yang T, Russo TA, Newton SM, Klebba PE. (2024) Siderophore-mediated iron acquisition by Klebsiella pneumoniae. Journal of bacteriology (Apr)e0002424.
- Slarve MJ, Bowler N, Burk E, Yan J, Carlino-MacDonald U, Russo TA, Luna BM, Spellberg B. (2024) Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy. JCI insight (Jan), 9(2).
- Russo TA, Alvarado CL, Davies CJ, Drayer ZJ, Carlino-MacDonald U, Hutson A, Luo TL, Martin MJ, Corey BW, Moser KA, Rasheed JK, Halpin AL, McGann PT, Lebreton F. (2024) Differentiation of hypervirulent and classical Klebsiella pneumoniae with acquired drug resistance. mBio (Jan)e0286723.
- Karah N, Mateo-Estrada V, Castillo-Ramírez S, Higgins PG, Havenga B, Khan W, Domingues S, Da Silva GJ, Poirel L, Nordmann P, Ambrosi C, Ma C, McClean S, Quiroga MP, Alvarez VE, Centron D, Zarrilli R, Kenyon JJ, Russo TA, Evans BA, Opazo-Capurro A, Rafei R, Hamze M, Daoud Z, Ahmad I, Rather PN, Hall RM, Wilharm G, Uhlin BE. (2023) The Acinetobacter baumannii website (Ab-web): a multidisciplinary knowledge hub, communication platform, and workspace. FEMS microbes (Jan), 4: xtad009. doi:10.1093/femsmc/xtad009
- Russo TA, Umland TC, Deng X, El Mazouni F, Kokkonda S, Olson R, Carlino-MacDonald U, Beanan J, Alvarado CL, Tomchick DR, Hutson A, Chen H, Posner B, Rathod PK, Charman SA, Phillips MA. (2022) Repurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumannii. Proceedings of the National Academy of Sciences of the United States of America (Dec), 119(51): e2213116119.
- Russo TA, Carlino-MacDonald U, Alvarado CL, Davies CJ, Barnes O, Trivedi G, Mathur P, Hutson A, Adams FG, Zang M, Ascari A, Eijkelkamp BA. (2022) Penicillin Binding Protein 7/8 Is a Potential Drug Target in Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy (Dec)e0103322.
- Kumar A, Yang T, Chakravorty S, Majumdar A, Nairn BL, Six DA, Marcondes Dos Santos N, Price SL, Lawrenz MB, Actis LA, Marques M, Russo TA, Newton SM, Klebba PE. (2022) Fluorescent sensors of siderophores produced by bacterial pathogens. The Journal of biological chemistry (Mar), 298(3): 101651. doi:10.1016/j.jbc.2022.101651
- Magda M, Bettoni S, Laabei M, Fairley D, Russo TA, Riesbeck K, Blom AM. (2022) Clinical Isolates of Acinetobacter spp. Are Highly Serum Resistant Despite Efficient Recognition by the Complement System. Frontiers in immunology (Jan), 13: 814193. doi:10.3389/fimmu.2022.814193
- Martin MJ, Corey BW, Sannio F, Hall LR, MacDonald U, Jones BT, Mills EG, Harless C, Stam J, Maybank R, Kwak Y, Schaufler K, Becker K, Hübner NO, Cresti S, Tordini G, Valassina M, Cusi MG, Bennett JW, Russo TA, McGann PT, Lebreton F, Docquier JD. (2021) Anatomy of an extensively drug-resistant Klebsiella pneumoniae outbreak in Tuscany, Italy. Proceedings of the National Academy of Sciences of the United States of America (Nov), 118(48).
- Russo TA, MacDonald U, Hassan S, Camanzo E, LeBreton F, Corey B, McGann P. (2021) An Assessment of Siderophore Production, Mucoviscosity, and Mouse Infection Models for Defining the Virulence Spectrum of Hypervirulent Klebsiella pneumoniae. mSphere (Mar), 6(2).
- Talyansky Y, Nielsen TB, Yan J, Carlino-Macdonald U, Di Venanzio G, Chakravorty S, Ulhaq A, Feldman MF, Russo TA, Vinogradov E, Luna B, Wright MS, Adams MD, Spellberg B. (2021) Capsule carbohydrate structure determines virulence in Acinetobacter baumannii. PLoS Pathog (Feb), 17(2): 1009291-1009291.
- Liu C, Du P, Xiao N, Ji F, Russo TA, Guo J. (2020) Hypervirulent Klebsiella pneumoniae is emerging as an increasingly prevalent K. pneumoniae pathotype responsible for nosocomial and healthcare-associated infections in Beijing, China. Virulence (Dec), 11(1)
- Marr CM, MacDonald U, Trivedi G, Chakravorty S, Russo TA. (2020) An Evaluation of BfmR-Regulated Antimicrobial Resistance in the Extensively Drug Resistant (XDR) Acinetobacter baumannii Strain HUMC1. Front Microbiol (Oct), 11: 595798-595798.
- Russo TA, MacDonald U. (2020) The Galleria mellonella Infection Model Does Not Accurately Differentiate between Hypervirulent and Classical Klebsiella pneumoniae. mSphere (Jan), 5(1)
- Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. (2020) Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother (Jan), 64(3)
- Mergenhagen KA, Wattengel BA, Skelly MK, Clark C, Russo TA. (2019) Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother (Dec)
- Russo TA, Marr CM. (2019) Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev (Jun), 32(3)
- Russo TA, Gulick AM. (2019) Aerobactin Synthesis Proteins as Antivirulence Targets in Hypervirulent Klebsiella pneumoniae. ACS Infect Dis (Apr)
- Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Russo TA, Balthasar JP. (2019) Antibody Dependent Enhancement of Acinetobacter baumannii Infection in a Mouse Pneumonia Model. J Pharmacol Exp Ther (Mar), 368(3)
- Marr CM, Russo TA. (2019) Hypervirulent Klebsiella pneumoniae: a new public health threat. Expert Rev Anti Infect Ther (Jan), 17(2)
- Sellick JA, Russo TA, Sellick, Jr JA. (2018) Getting hypervirulent Klebsiella pneumoniae on the radar screen. Curr Opin Infect Dis (Aug), 31(4)
- Russo TA, Olson R, Fang CT, Stoesser N, Miller M, Hutson A, Barker JH, La Hoz RM, Johnson JR. (2018) Identification of biomarkers for the differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae. J Clin Microbiol (Jun)
- Diep JK, Russo TA, Rao GG. (2018) Mechanism-Based Disease Progression Model Describing Host-Pathogen Interactions During the Pathogenesis of Acinetobacter baumannii Pneumonia. CPT Pharmacometrics Syst Pharmacol (May)
- Johnson JR, Russo TA. (2018) Molecular Epidemiology of Extraintestinal Pathogenic Escherichia coli. EcoSal Plus (Apr), 8(1)
- Johnson JR, Russo TA. (2018) Acute Pyelonephritis in Adults. N Engl J Med (Jan), 378(1)
- Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Balthasar JP, Russo TA. (2017) The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies. Infect Immun (Dec), 85(12)
- Bulger J, MacDonald U, Olson R, Beanan J, Russo TA. (2017) Metabolite Transporter PEG344 Is Required for Full Virulence of Hypervirulent Klebsiella pneumoniae Strain hvKP1 after Pulmonary but Not Subcutaneous Challenge. Infect Immun (Oct), 85(10)
- Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, Hsieh S, Yeshoua B, Pascual B, Vinogradov E, Hujer KM, Domitrovic TN, Bonomo RA, Russo TA, Lesczcyniecka M, Schneider T, Spellberg B. (2017) Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis. J Infect Dis (Aug), 216(4)
- Diep JK, Jacobs DM, Sharma R, Covelli J, Bowers DR, Russo TA, Rao GG. (2017) Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother (Feb), 61(2)
- Russo TA, Manohar A, Beanan JM, Olson R, MacDonald U, Graham J, Umland TC. (2016) The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii. mSphere (May), 1(3)
- Russo TA, Spellberg B, Johnson JR. (2016) Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections. J Infect Dis (Mar), 213(6)
- Sutton KA, Breen J, Russo TA, Schultz LW, Umland TC. (2016) Crystal structure of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase from the ESKAPE pathogen Acinetobacter baumannii. Acta Crystallogr F Struct Biol Commun (Mar), 72(Pt 3)
- Marks LR, Dodd H, Russo TA, Berenson CS. (2016) Burkholderia ginsengisoli bacteraemia: emergence of a novel pathogen. BMJ Case Rep (Feb), 2016
- Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. (2015) Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun (Aug), 83(8)
- Sutton KA, Breen J, MacDonald U, Beanan JM, Olson R, Russo TA, Schultz LW, Umland TC. (2015) Structure of shikimate kinase, an in vivo essential metabolic enzyme in the nosocomial pathogen Acinetobacter baumannii, in complex with shikimate. Acta Crystallogr D Biol Crystallogr (Aug), 71(Pt 8)
- Vallejo JA, Beceiro A, Rumbo-Feal S, Rodríguez-Palero MJ, Russo TA, Bou G. (2015) Optimisation of the Caenorhabditis elegans model for studying the pathogenesis of opportunistic Acinetobacter baumannii. Int J Antimicrob Agents (Jul)
- Russo TA, Olson R, Macdonald U, Metzger D, Maltese LM, Drake EJ, Gulick AM. (2014) Aerobactin Mediates Virulence and Accounts for Increased Siderophore Production under Iron-Limiting Conditions by Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae. Infect Immun (Jun), 82(6)
- Russo TA, Olson R, MacDonald U, Metzger D, Maltese LM, Drake EJ, Gulick AM. (2014) Aerobactin Mediates Virulence and Accounts for the Increased Siderophore Production Under Iron Limiting Conditions by Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae. Infection and Immunity (Jun), 82(6)
- Patel PK, Russo TA, Karchmer AW. (2014) Hypervirulent Klebsiella pneumoniae. Open Forum Infect Dis (Mar), 1(1)
- Umland TC, Schultz LW, Russo TA. (2014) Re-evaluating the approach to drug target discovery in multidrug-resistant Gram-negative bacilli. Future Microbiol (Jan), 9(10)
- Johnson JR, Russo TA, Drawz SM, Clabots C, Olson R, Kuskowski MA, Rosen H. (2013) OxyR Contributes to the Virulence of a Clonal Group A Escherichia coli Strain (O17:K+:H18) in Animal Models of Urinary Tract Infection, Subcutaneous Infection, and Systemic Sepsis. Microb Pathog (Jul)
- Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marchall NR, Campagnari AA. (2013) The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infection and Immunity (Mar), 81(3)
- Russo TA, Gill SR. (2013) Draft Genome Sequence of the Hypervirulent Klebsiella pneumoniae Strain hvKP1, Isolated in Buffalo, New York. Genome Announc (Mar), 1(2)
- Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. (2013) The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infection and immunity (Mar), 81(3): 915-22. doi:10.1128/IAI.01184-12
- Shon AS, Bajwa RP, Russo TA. (2013) Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: A new and dangerous breed. Virulence (Feb), 4(2)
- Umland TC, Schultz LW, Macdonald U, Beanan JM, Olson R, Russo TA,. (2012) In Vivo-Validated Essential Genes Identified in Acinetobacter baumannii by Using Human Ascites Overlap Poorly with Essential Genes Detected on Laboratory Media. MBio (Aug), 3(4)
- Shon AS, Russo TA. (2012) Hypervirulent Klebsiella Pneumoniae: The Next Superbug?. Future Microbiol (Jun), 7
- Pomakova DK, Hsiao CB, Beanan JM, Olson R, MacDonald U, Keynan Y, Russo TA. (2012) Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. Eur J Clin Microbiol Infect Dis (Jun), 31(6)
- Kong Q, Beanan JM, Olson R, MacDonald U, Shon AS, Metzger DJ, Pomakov AO, Russo TA. (2012) Biofilm formed by a hypervirulent (hypermucoviscous) variant of Klebsiella pneumoniae does not enhance serum resistance or survival in an in vivo abscess model. Virulence (May), 3(3)
- Kong Q, Beanan JM, Olson R, Macdonald U, Shon AS, Metzger DJ, Pomakov AO, Russo TA. (2012) Biofilm formed by a hypervirulent (hypermucoviscous) variant of Klebsiella pneumoniae does not enhance serum resistance or survival in an in vivo abscess model. Virulence (May), 3(3): 309-18. doi:10.4161/viru.20383
- Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. (2012) Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One (Jan), 7(1)
- Russo TA, Shon AS, Beanan JM, Olson R, Macdonald U, Pomakov AO, Visitacion MP. (2011) Hypervirulent k. Pneumoniae secretes more and more active iron-acquisition molecules than "classical" k. Pneumoniae thereby enhancing its virulence. PLoS One (Oct), 6(10)
- Russo TA, Page MG, Beanan JM, Olson R, Hujer AM, Hujer KM, Jacobs M, Bajaksouzian S, Endimiani A, Bonomo RA. (2011) In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother (Apr), 66(4)
- Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. (2010) The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun (Sep), 78(9)
- Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St Michael F, Vinogradov EV, Campagnari AA. (2010) Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect Immun (May), 78(5)
- Naik NH, Russo TA. (2009) Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis (Dec), 49(11)
- Chattopadhyay S, Weissman SJ, Minin VN, Russo TA, Dykhuizen DE, Sokurenko EV. (2009) High frequency of hotspot mutations in core genes of Escherichia coli due to short-term positive selection. Proc Natl Acad Sci U S A (Jul), 106(30)
- Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberan SL, Luke NR, Schultz LW, Umland TC. (2009) Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J Infect Dis (Feb), 199(4)
- Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ. (2009) Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine (Jan), 27(3)
- Russo TA, Carlino-MacDonald U. (2008) Extraintestinal pathogenic isolates of Escherichia coli do not possess active IgA1, IgA2, sIgA or IgG proteases. FEMS Immunol Med Microbiol (Jun), 53(1)
- Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. (2008) Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect Immun (Jan), 76(8)
- Russo TA, Davidson BA, Beanan JM, Olson R, Holm BA, Notter RH, Knight PR. (2007) Capsule and O-antigen from an extraintestinal isolate of Escherichia coli modulate cytokine levels in rat macrophages in vitro and in a rat model of pneumonia. Exp Lung Res (Sep), 33(7)
- Nazareth H, Genagon SA, Russo TA. (2007) Extraintestinal pathogenic Escherichia coli survives within neutrophils. Infect Immun (Jun), 75(6)
- Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. (2007) A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine (May), 25(19)
- Segal BH, Davidson BA, Hutson AD, Russo TA, Holm BA, Mullan B, Habitzruther M, Holland SM, Knight PR. (2007) Acid aspiration-induced lung inflammation and injury are exacerbated in NADPH oxidase-deficient mice. Am J Physiol Lung Cell Mol Physiol (Mar), 292(3)
- Russo TA, Wang Z, Davidson BA, Genagon SA, Beanan JM, Olson R, Holm BA, Knight PR, Chess PR, Notter RH. (2007) Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol (Mar), 292(3)
- Russo TA, Johnson JR. (2006) Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Expert Rev Vaccines (Feb), 5(1)
- Johnson JR, Russo TA. (2005) Molecular epidemiology of extraintestinal pathogenic (uropathogenic) Escherichia coli. Int J Med Microbiol (Oct), 295(6-7)
- Russo TA, Davidson BA, Genagon SA, Warholic NM, Macdonald U, Pawlicki PD, Beanan JM, Olson R, Holm BA, Knight PR. (2005) E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol (Aug), 289(2)
- Raghavendran K, Davidson BA, Mullan BA, Hutson AD, Russo TA, Manderscheid PA, Woytash JA, Holm BA, Notter RH, Knight PR. (2005) Acid and particulate-induced aspiration lung injury in mice: importance of MCP-1. Am J Physiol Lung Cell Mol Physiol (Jul), 289(1)
- Davidson BA, Stewart CC, Russo TA, Chess PR, Knight PR. (2005) Discrimination of resident and infiltrated alveolar macrophages by flow cytometry in influenza A virus-infected mice. Exp Lung Res (Apr), 31(3)
- Davidson BA, Knight PR, Wang Z, Chess PR, Holm BA, Russo TA, Hutson A, Notter RH. (2005) Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol (Apr), 288(4)
- Johnson JR, Russo TA. (2004) Molecular Epidemiology of Extraintestinal Pathogenic Escherichia coli. EcoSal Plus (Dec), 1(1).
- Knight PR, Davidson BA, Nader ND, Helinski JD, Marschke CJ, Russo TA, Hutson AD, Notter RH, Holm BA. (2004) Progressive, severe lung injury secondary to the interaction of insults in gastric aspiration. Exp Lung Res (Oct), 30(7)
- Manderscheid PA, Bodkin RP, Davidson BA, Jensen E, Russo TA, Knight PR. (2004) Bacterial clearance and cytokine profiles in a murine model of postsurgical nosocomial pneumonia. Clinical and diagnostic laboratory immunology (Jul), 11(4): 742-51. doi:10.1128/CDLI.11.4.742-751.2004
- Manderscheid PA, Bodkin RP, Davidson BA, Jensen E, Russo TA, Knight PR. (2004) Bacterial clearance and cytokine profiles in a murine model of postsurgical nosocomial pneumonia. Clin Diagn Lab Immunol (Jul), 11(4)
- Rotta AT, Shiley KT, Davidson BA, Helinski JD, Russo TA, Knight PR. (2004) Gastric acid and particulate aspiration injury inhibits pulmonary bacterial clearance. Crit Care Med (Mar), 32(3)
- Rotta AT, Shiley KT, Davidson BA, Helinski JD, Russo TA, Knight PR. (2004) Gastric acid and particulate aspiration injury inhibits pulmonary bacterial clearance. Critical care medicine (Mar), 32(3): 747-54.
- Johnson JR, Gajewski A, Lesse AJ, Russo TA. (2003) Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections. J Clin Microbiol (Dec), 41(12)
- Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. (2003) The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infection and immunity (Dec), 71(12): 7164-9. doi:10.1128/IAI.71.12.7164-7169.2003
- Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. (2003) The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun (Dec), 71(12)
- Johnson JR, Gajewski A, Lesse AJ, Russo TA. (2003) Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections. Journal of clinical microbiology (Dec), 41(12): 5798-802. doi:10.1128/JCM.41.12.5798-5802.2003
- Russo TA, Davidson BA, Topolnycky DM, Olson R, Morrill SA, Knight PR, Murphy PM. (2003) Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain. Infection and immunity (Nov), 71(11): 6435-45. doi:10.1128/IAI.71.11.6435-6445.2003
- Russo TA, Davidson BA, Topolnycky DM, Olson R, Morrill SA, Knight PR, Murphy PM. (2003) Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain. Infect Immun (Nov), 71(11)
- Russo TA, Davidson BA, Carlino-MacDonald UB, Helinski JD, Priore RL, Knight PR. (2003) The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia. FEMS microbiology letters (Sep), 226(2): 355-61.
- Russo TA, Davidson BA, Carlino-MacDonald UB, Helinski JD, Priore RL, Knight PR. (2003) The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia. FEMS Microbiol Lett (Sep), 226(2)
- Russo TA, Johnson JR. (2003) Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect (Apr), 5(5)
- Russo TA, Johnson JR. (2003) Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes and infection (Apr), 5(5): 449-56.
- Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Barnard TJ, Johnson JR. (2002) IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli. Infection and immunity (Dec), 70(12): 7156-60. doi:10.1128/IAI.70.12.7156-7160.2002
- Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Barnard TJ, Johnson JR. (2002) IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli. Infect Immun (Dec), 70(12)
- Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR, Beers MF, Atochina EN, Notter RH, Holm BA. (2002) Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia. American journal of physiology. Lung cellular and molecular physiology (Sep), 283(3): L655-63.
- Johnson JR, Russo TA. (2002) Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections. The Journal of infectious diseases (Sep), 186(6): 859-64.
- Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR, Beers MF, Atochina EN, Notter RH, Holm BA. (2002) Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol (Sep), 283(3)
- Johnson JR, Russo TA. (2002) Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections. J Infect Dis (Sep), 186(6)
- Johnson JR, Russo TA. (2002) Extraintestinal pathogenic Escherichia coli: "the other bad E coli". J Lab Clin Med (Mar), 139(3)
- Johnson JR, Russo TA. (2002) Extraintestinal pathogenic Escherichia coli: 'the other bad E coli'. J Lab Clin Med (Mar), 139(3)
- Russo TA, Carlino UB, Johnson JR. (2001) Identification of a new iron-regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of Escherichia coli. Infection and immunity (Oct), 69(10): 6209-16. doi:10.1128/IAI.69.10.6209-6216.2001
- Russo TA, Carlino UB, Johnson JR. (2001) Identification of a new iron-regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of Escherichia coli. Infect Immun (Oct), 69(10)
- Johnson JR, O'Bryan TT, Delavari P, Kuskowski M, Stapleton A, Carlino U, Russo TA. (2001) Clonal relationships and extended virulence genotypes among Escherichia coli isolates from women with a first or recurrent episode of cystitis. The Journal of infectious diseases (May), 183(10): 1508-17.
- Johnson JR, O'Bryan TT, Delavari P, Kuskowski M, Stapleton A, Carlino U, Russo TA. (2001) Clonal relationships and extended virulence genotypes among Escherichia coli isolates from women with a first or recurrent episode of cystitis. J Infect Dis (May), 183(10)
- Johnson JR, Delavari P, Stell AL, Whittam TS, Carlino U, Russo TA. (2001) Molecular comparison of extraintestinal Escherichia coli isolates of the same electrophoretic lineages from humans and domestic animals. The Journal of infectious diseases (Jan), 183(1): 154-9.
- Johnson JR, Delavari P, Stell AL, Whittam TS, Carlino U, Russo TA. (2001) Molecular comparison of extraintestinal Escherichia coli isolates of the same electrophoretic lineages from humans and domestic animals. J Infect Dis (Jan), 183(1)
- Johnson JR, O'Bryan TT, Low DA, Ling G, Delavari P, Fasching C, Russo TA, Carlino U, Stell AL. (2000) Evidence of commonality between canine and human extraintestinal pathogenic Escherichia coli strains that express papG allele III. Infect Immun (Jun), 68(6)
- Russo TA, Davidson BA, Priore RL, Carlino UB, Helinski JD, Knight PR. (2000) Capsular polysaccharide and O-specific antigen divergently modulate pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis in rats. Infect Immun (May), 68(5)
- Johnson JR, Russo TA, Tarr PI, Carlino U, Bilge SS, Vary JC, Stell AL. (2000) Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN(E. coli), among Escherichia coli isolates from patients with urosepsis. Infect Immun (May), 68(5)
- Russo TA, Johnson JR. (2000) Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis (May), 181(5)
- Johnson JR, Stell AL, Scheutz F, O'Bryan TT, Russo TA, Carlino UB, Fasching C, Kavle J, Van Dijk L, Gaastra W. (2000) Analysis of the F antigen-specific papA alleles of extraintestinal pathogenic Escherichia coli using a novel multiplex PCR-based assay. Infect Immun (Mar), 68(3)
- Russo TA, Carlino UB, Mong A, Jodush ST. (1999) Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect Immun (Oct), 67(10)
- Luke NR, Thomas Russo, Luther N, Anthony Campagnari. (1999) Use of an isogenic mutant constructed in Moraxella catarrhalis To identify a protective epitope of outer membrane protein B1 defined by monoclonal antibody 11C6. Infect Immun (Feb), 67(2)
- Russo TA, Mylotte D. (1998) Expression of the K54 and O4 specific antigen has opposite effects on the bactericidal activity of squalamine against an extraintestinal isolate of Escherichia coli. FEMS Microbiol Lett (May), 162(2)
- Johnson JR, Brown JJ, Carlino UB, Russo TA. (1998) Colonization with and acquisition of uropathogenic Escherichia coli as revealed by polymerase chain reaction-based detection. J Infect Dis (Apr), 177(4)
- Johnson JR, Russo TA, Brown JJ, Stapleton A. (1998) papG alleles of Escherichia coli strains causing first-episode or recurrent acute cystitis in adult women. J Infect Dis (Jan), 177(1)
- Russo TA, Wenderoth S, Carlino UB, Merrick JM, Lesse AJ. (1998) Identification, genomic organization, and analysis of the group III capsular polysaccharide genes kpsD, kpsM, kpsT, and kpsE from an extraintestinal isolate of Escherichia coli (CP9, O4/K54/H5). J Bacteriol (Jan), 180(2)
- Wang Y, Russo TA, Kwon O, Chanock S, Rumsey SC, Levine M. (1997) Ascorbate recycling in human neutrophils: induction by bacteria. Proc Natl Acad Sci U S A (Dec), 94(25)
- Johnson JR, Stapleton AE, Russo TA, Scheutz F, Brown JJ, Maslow JN. (1997) Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG. Infect Immun (Jun), 65(6)
- Johnson JR, Russo TA, Scheutz F, Brown JJ, Zhang L, Palin K, Rode C, Bloch C, Marrs CF, Foxman B. (1997) Discovery of disseminated J96-like strains of uropathogenic Escherichia coli O4:H5 containing genes for both PapG(J96) (class I) and PrsG(J96) (class III) Gal(alpha1-4)Gal-binding adhesins. J Infect Dis (Apr), 175(4)
- Russo TA, Jodush ST, Brown JJ, Johnson JR. (1996) Identification of two previously unrecognized genes (guaA and argC) important for uropathogenesis. Mol Microbiol (Oct), 22(2)
- Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. (1995) Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis (Aug), 172(2)
- Thomas Russo, Sharma G, Brown CR, Anthony Campagnari. (1995) Loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo. Infect Immun (Apr), 63(4)
- Russo TA, Sharma G, Weiss J, Brown C. (1995) The construction and characterization of colanic acid deficient mutants in an extraintestinal isolate of Escherichia coli (O4/K54/H5). Microb Pathog (Apr), 18(4)
- Russo TA, Liang Y, Cross AS. (1994) The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo. J Infect Dis (Jan), 169(1)
- Russo TA, Singh G. (1993) An extraintestinal, pathogenic isolate of Escherichia coli (O4/K54/H5) can produce a group 1 capsule which is divergently regulated from its constitutively produced group 2, K54 capsular polysaccharide. J Bacteriol (Dec), 175(23)
- Godoy VG, Dallas MM, Russo TA, Malamy MH. (1993) A role for Bacteroides fragilis neuraminidase in bacterial growth in two model systems. Infect Immun (Oct), 61(10)
- Russo TA, Moffitt MC, Hammer CH, Frank MM. (1993) TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity. Infect Immun (Aug), 61(8)
- Russo TA, Guenther JE, Wenderoth S, Frank MM. (1993) Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (Jul), 9(2)
- Russo TA, Thompson JS, Godoy VG, Malamy MH. (1990) Cloning and expression of the Bacteroides fragilis TAL2480 neuraminidase gene, nanH, in Escherichia coli. J Bacteriol (May), 172(5)
- Russo TA, Cook S, Gorbach SL. (1988) Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother (Sep), 32(9)
Books and Book Chapters:
- Russo TA. (2015) In: Actinomycosis and Whipple‘s Disease.
- Russo TA. (2015) In: Actinomycosis.
- Russo TA Johnson JR. (2015) In: Diseases caused by gram-negative enteric bacilli.
- Russo TA. (2014) In: Agents of Actinomycosis.
- Russo TA. (2009) In: Agents of Actinomycosis.
- Bianchine PJ, Russo TA. (1992) The role of epidemic infectious diseases in the discovery of America.
Professional Memberships:
- Fellow, American Association for the Advancement of Science; Elected Fellow-4/2024 (2006–present)
- Fellow, Infectious Diseases Society of America (1993–present)
- American Society of Microbiology (1989–present)
Presentations:
- "“Working towards a pragmatic definition of hvKp”." Pan American Health Organization meeting: “Dissemination of hypervirulent Klebsiella pneumoniae ST23 K1: Preparation for detection and containment.” (2024)
- "“Everything you wanted to ask about Long COVID but were afraid to ask”" Catholic Health System Grand Rounds (2023)
- "“Everything you wanted to know about Long COVID but were afraid to ask.”" Dept. of Medicine-Grand Rounds (2023)
- "The hunt for hypervirulent Klebsiella pneumoniae-specific virulence factors" Klebsiella virtual seminar series (2022)
- "A case of hypervirulent Klebsiella pneumoniae" Infectious Diseases Grand Rounds at the University of Iowa Hospitals and Clinics (2022)
- "“A surprise within a surprise.”" UB MD-PhD seminar series (2021)
- "COVID Pandemic" Buffalo Virtual Summer Research Day (2021)
- "Is the Pandemic Over? Where We Stand with COVID--19" Medical Grand Rounds (2021)
- "COVID Pandemic" UB School of Public Health and Health Professions Commencement (2021)
- "“Career development, COVID, and Q&A.”" Keynote speaker at the GSPHA Graduate Research Symposium. (2021)
- "“COVID-19 update/Q&A”." Family Medicine Grand Rounds (2021)
- "“Post-CTSI forum reflections: UB experts discuss COVID-19 strategies and lessons.”" CTSI COVID Forum (2021)
- "Acute pyelonephritis in adults" Invited talk at the 70th Northeastern Section of the American Urologic Association (2018)
- "Hypervirulent Klebsiella pneumoniae: An emerging pathotype poised to inflict global havoc" Invited talk at the 28th European Congress of Clinical Microbiology and Infectious Diseases (2018)
- "Hypervirulent Klebsiella pneumoniae: The next plague?" Invited talk: Kansas State (2018)
- "Hypervirulent Klebsiella pneumoniae: A dangerous pathotype poised to create global havoc" Invited to present at intramural NIH (2014)
- "Catheter-associated UTIs: Can we make them extinct?" Invited talk at the 21st National Conference on Nosocomial Infection of the Chinese Preventive Medicine Association (CPMA) and the 8th Shanghai International Forum of Infection Control (SIFIC) (2012)
- "Extreme and multi-drug resistance in gram-negative bacilli" Invited talk at Shanghai Public Health Clinical Center by Dr. Lu (2012)
- "Hypervirulent Klebsiella pneumoniae: Beginning to understand the next potential superbug" Invited talk at Beijing You’An Hospital by Dr. Yu (2012)
- "Numerous" Grand Rounds (Medicine et al) Infectious Diseases Clinical and research conferences
Service Activities:
- JSMBS Research day; Facilitator (2024)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2024)
- Empire Innovation Program; grant reviewer (2024)
- International Visitor Leadership program – US Dept of State. Establishment of a National Public Health Institute in Uzbekistan. A Project for Uzbekistan.; New York State representative (2024)
- UB COVID-19 pandemic – After action exercise; Participant (2024)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2023)
- Search committee for the Chair of the Department of Medicine; Co-Chair (2023)
- VA Centralized Promotion review; Promotion review (2023)
- VA Career Scientist Midterm Report Review; Report review (2023)
- JSMBS Research day; Facilitator (2023)
- Search committee for Associate Vice President for Health Sciences Research Administration and Finance; Chair (2022–2023)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2022)
- Communication Director-School of Medicine search; member (2022)
- DEI Supplements Review, Department of Veterans Affairs; reviewer (2022)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2022)
- VA Centralized Promotion review; Promotion review (2022)
- Dean’s COVID Research Integration Work Group; member (2021–2022)
- COVID Surge Committee; member (2021–2022)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2021)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2021)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2020)
- COVID-19 Sewage monitoring committee; member (2020–2022)
- COVID-19 Lifelink committee; member (2020–2021)
- UB Press Conferences-Town Halls relating to COVID-19; Panelist (2020–present)
- COVID-19 Screening, Testing and Contact Tracing Protocol Committee; member (2020–2022)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2020)
- Wrote or reviewed and edited numerous COVID-19 related articles-FAQ for UB Communications; writer-editor (2020–present)
- Advised on various COVID infection control practices and policies on isolation and quarantine; Expert Advisor (2020–present)
- NIH Special Emphasis Panel/Scientific Review Group 2020/05 ZRG1 IDM-Y (82) S meeting- Exploration of antimicrobial therapeutics and resistance; grant reviewer (2020)
- webinars, talks; Resource various schools, institutions, and businesses during the COVID pandemic (2020–present)
- >1,450 print, radio, TV media interviews. Local, national, and international. Educational talks, webinars, videos to various community groups; Resource and educator during the COVID pandemic (2020–present)
- INFB Merit Review Grants, Department of Veterans Affairs; grant reviewer (2019)
- The Netherlands Organisation for Scientific Research-Vici proposal; grant reviewer (2018)
- NIH-Partnerships for the Development of Vaccines and Immunoprophylactics Targeting Multiple Antibiotic-Resistant Bacteria; grant reviewer (2018)
- Vice Chair of Finance, multiple monthly meeting on various aspects of the PP (2017–2019)
- Co-Chair- Committee to write Standards 1 and 5 for the DCI document for the School of Medicine’s LCME re-accreditation; Co-Chair (2017–2018)
- Executive Committee for the School of medicine’s LCME re-accreditation; member (2017–2018)
- Faculty Council Governance body for the Jacobs School of Medicine and Biomedical Sciences; President (2016–2017)
- Medical Student Annual Research Forum; reviewer (2015–present)
- Merit Review Grants, Depart. Veterans Affairs, Infect. Dis. B; grant reviewer (2013–2016)
- UB-Capital Medical University (Beijing, China) exchange program; Director (2012–present)
- Institut Pasteur “Transverse Research Programs; grant reviewer (2012)
- CME Conference Planning Committee; member (2012–2018)
- Vice Chair of Business Operations, multiple monthly meeting on finance related matters; Vice Chair of Business Operations (2012–2017)
- T35 Steering Committee-Research in Infectious Diseases, Microbiology & Immunology for Medical Students; Committee Member (2011–present)
- UBMDIM Board of Directors Practice plan board for the Department of Medicine; Board Member (2011–2019)
- interviews for print, radio, TV media outlets; Resource for non-COVID infectious diseases issues (2011–present)
- Committee for Evaluation of MD-PhD Training Program; Chair (2011)
- Ad Hoc Committee for Qualified Promotions; Committee Member (2010–2013)
- Faculty Senate; Member (2009–2011)
- Council Undergraduate Research Academy; Advisory Committee (2009–2010)
- NIH; NIH-Host Interactions with Bacterial Pathogens;; Ad Hoc Reviewer (2009)
- New York State; New York State_Empire Clinical Research Investigator Program;; Grant Reviewer (2008)
- Undergraduate Research Academy (2008–2009)
- Canadian Institutes of Health Research; Canadian Institutes of Health Research-Infectious Diseases;; Ad Hoc Reviewer (2007)
- University Faculty Recognition Committee; Committee Member (2007–2010)
- NIH; NIH SEP ZRG1 RUS-B (05);; Grant Reviewer (2006)
- NIH; NIH-Host Interactions with Bacterial Pathogens;; Panel Member (2005)
- Veterans Administration; VA-Infectious Diseases B;; Panel Member (2004–2007)
- MD-PhD Steering Committee; Committee Member (2004–2020)
- USDA; United States Department of Agriculture;; Ad Hoc Reviewer (2004)
- NIH; NIH Bacteriology & Mycology1 Study section;; Panel Member (2003)
- NIH; NIH Lung Biology & Pathology Study Section;; Panel Member (2003)
- Department of Defense; Defense Health-Related Research Program;; Ad Hoc Reviewer (2000)
- Faculty Council Steering Committee; Member (2000–2002)
- VAMC Institutional Animal Care and Usage Committee; Chair (2000–2003)
- Faculty Council; Department Representative (1999–2001)
- NIH; NIH Micro. & Immuno. Sciences SEP;; Panel Member (1999)
- University Biosafety Committee; Committee Member (1999–present)
- NIH; NIH Micro. & Immuno. Sciences SEP;; Panel Member (1998)
- Medical Student Mentoring Program; Student Mentor (1997–2003)
- Veterans Administration; VA-Infectious Diseases B;; Ad Hoc Reviewer (1997)
- Internal reviewer for the 14th edition of Harrison’s Principles of Internal Medicine; reviewer (1996)
- 10-15 manuscripts per annum I have reviewed manuscripts for 59 different journals over my academic career, including the NEJM, JAMA, Lancet Infectious Diseases, Nature, PLos Pathogens, JID, CID, and Molec Microbiol.; manuscript reviewer (1994–present)